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REPORT
Lethal Congenital Contractural Syndrome Type 2 (LCCS2)
Is Caused by a Mutation in ERBB3 (Her3), a Modulator
of the Phosphatidylinositol-3-Kinase/Akt Pathway
Ginat Narkis, Rivka Oﬁr, Esther Manor, Daniella Landau, Khalil Elbedour, and Ohad S. Birk
Lethal congenital contractural syndrome type 2 (LCCS2) is an autosomal recessive neurogenic form of arthrogryposis
that is associated with atrophy of the anterior horn of the spinal cord. We previously mapped LCCS2 to 6.4 Mb on
chromosome 12q13 and have now narrowed the locus to 4.6 Mb. We show that the disease is caused by aberrant splicing
of ERBB3, which leads to a predicted truncated protein. ERBB3 (Her3), an activator of the phosphatidylinositol-3-kinase/
Akt pathway—regulating cell survival and vesicle trafﬁcking—is essential for the generation of precursors of Schwann
cells that normally accompany peripheral axons of motor neurons. Gain-of-function mutations in members of the
epidermal growth-factor tyrosine kinase–receptor family have been associated with predilection to cancer. This is the
ﬁrst report of a human phenotype resulting from loss of function of a member of this group.
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Lethal congenital contractual syndrome type 2 (LCCS2
[MIM 607598]), a neonatally lethal form of arthrogryposis
presenting in two Israeli-Bedouin kindreds1 (families A
and B) (ﬁg. 1), is characterized by multiple joint contrac-
tures, anterior horn atrophy in the spinal cord, and a
unique feature of a markedly distended urinary bladder.
The phenotype suggests a spinal cord neuropathic etiol-
ogy.2 Through genomewide linkage analysis, we previ-
ously mapped this syndrome to 6 cM (6.4 Mb) on chro-
mosome 12q13 between markers D12S325 and D12S1072
(maximum LOD score of at ),1Z p 9.23 vp 0max
We now have narrowed the disease-associated locus, us-
ing additionalmarkers between andﬂankingD12S325 and
D12S1072. Eleven microsatellite markers were selected
from public genome databases (Marshﬁeld, Ge´ne´thon,
and deCODE Genetic maps): D12S1712, D12S398,
D12S103, D12S1691, D12S72, D12S104, AFMa122yc5,
D12S329, D12S375, D12S1052, and D12S1662. The lower
boundaries were determined on the basis of analysis of
individual 61 (ﬁg. 1). This individual was homozygous for
the common haplotype between D12S1635 andD12S305.
As seen in ﬁgure 2, on the basis of his and his mother’s
haplotypes and of the results for markers D12S305,
D12S1072, D12S1662, and D12S1291, we could assume
that a crossing-over event had occurred proximal to
marker D12S305 in the affected individual. Thus, the re-
gion of homozygosity common to affected individuals in
both families was narrowed to 5.3 cM, corresponding to
4.6 Mb between markers D12S325 and D12S305. Markers
D12S1712, D12S398, D12S329, D12S375, D12S1052, and
D12S1662 were demonstrated to be outside the deﬁned
boundaries of the region of homozygosity (results not
shown). The possibility that the disease-associated locus
is between D12S305 and D12S1072 cannot be ruled out,
but it is less likely, since this would require two crossing-
over events occurring in individual 61 (ﬁg. 2).
In an attempt to identify the speciﬁc molecular defect
leading to the phenotype, we sequenced 61 of the 162
genes in the linkage interval (according to Map Viewer,
build 36, and University of California–Santa Cruz [UCSC]
Genome Browser). Blood samples were obtained with in-
formed consent after approval was received from the So-
roka University Medical Center institutional reviewboard.
DNA was isolated from whole blood, tissue samples, or
cultured cells, with use of the PUREGENE DNA Isolation
Kit per the manufacturer’s instructions (Gentra Systems).
RNA was extracted from Epstein-Barr virus–transformed
lymphoblastoid cells generated from affected individuals,
with use of standard methods. The coding sequences were
ampliﬁed from genomic DNA or cDNA with PCR primers
designed using the Primer3 program. PCR products were
subjected to agarose-gel electrophoresis and gel extraction
(QIAGEN), followed by sequencing with either the for-
ward or reverse primer on an ABI PRISM 377 DNA Se-
quencer (Applied Biosystems). Results were analyzedusing
ChromasPro software, and the obtained DNA sequences
were compared with published sequences by use of BLAST.
Genes selected to be analyzed were of several categories:
genes that were previously known to be expressed in the
spinal cord or to take part in neurogenesis; genes that
encode proteins that participate in the function of cells
of the neural system, such as NEUROD4, GEFT, and TAC3;
and genes known to be involved in development of the
nervous system, such as NAB2, GDF11, and several HOXC
Figure 1. Israeli-Bedouin kindreds affected with LCCS2. Blackened and unblackened symbols represent affected and unaffected individuals, respectively. The numbers denote
individuals whose DNA samples were analyzed. A, Pedigree of family A. B, Pedigree of family B.
www.ajhg.org The American Journal of Human Genetics Volume 81 September 2007 591
Figure 2. Linkage results for chromosome 12 of two nuclear families of family A. The haplotype showing the homozygosity region is
boxed. The arrow indicates a crossing-over event. The lower boundary was determined on the basis of analysis of individual 61.
genes. Another form of autosomal recessive arthrogry-
posis, arthrogryposis–renal dysfunction–cholestasis syn-
drome (ARC [MIM 208085]), is caused bymutations in the
VPS33B gene.3 VPS33B encodes an Sec1/Munc-18 (SM)
protein that belongs to a subfamily of class C vacuolar
sorting proteins (VPSs)3,4 that are essential for intracellular
membrane-fusion reactions and are associated with severe
vacuolar protein–sorting and –morphology defects.5 We
therefore also sequenced genes within the LCCS2 linkage
interval that are known to be associated with vesicle trans-
port, such as COPZ1, DNAJC14, and OS9. No mutations
were found in the coding sequence or within the intron-
exon boundaries of any of the genes sequenced (listed in
table 1).
In a study6(in this issue) done in parallel with the one de-
scribed here, we demonstrated through genomewide link-
age analysis that a similar form of autosomal recessive
lethal congenital contractural syndrome (LCCS3) with-
out the neurogenic bladder is caused by a mutation in
PIP5K1C, which encodes phosphatidylinositol-4-phos-
phate 5-kinase, type I, gamma (PIPKIg). Because the phe-
notypes of LCCS2 and LCCS3 are similar, we sequenced
genes in the LCCS2 interval that are related to PIP5K1C.
PIP5K1C is involved in signal transduction through the
phosphatidylinositol signaling pathway; PIP5K1C cata-
lyzes the phosphorylation of phosphatidylinositol-4-
phosphate (PI4P) to generate phosphatidylinositol-4,5-
bisphosphate (PIP2),
7,8 a substrate for a variety of enzymes
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Table 1. Candidate Genes in the LCCS2
Interval
Position
(bp) Gene
Type of DNA
Sequenceda
52618843 HOXC13 C
52634981 HOXC12 G
52634981 HOXC12 C
52653196 HOXC11 C
52665221 HOXC10 C
52680144 HOXC9 C
52689157 HOXC8 C
52696940 HOXC4 C
52708467 HOXC6 C
52713099 HOXC5 C
53005178 COPZ1 C
53229671 PDE1B C
53259302 PPP1R1A C
53699889 NEUROD4 G
54396088 BLOC1S1 C
54423335 GDF11 G
54437325 DNAJC14 C
54498121 ORMDL2 C
54611213 DGKA C
54654027 RAB5B C
54704791 ZNFN1A4 C
54760154 ERBB3 G
54784692 PA2G4 C
54798297 NP_116175.1 C
54838413 MYL6 C
54884555 RNF41 C
54904418 NP_076973.1 C
54910805 SLC39A5 C
54918270 Q8NB46 C
54990484 TMEM4 C
54996988 USP52 C
55097177 TIMELESS C
55131149 MIP G
55148618 Q8WZ21 C
55151009 GLS2 C
55343403 TEBP C
55392484 NACA C
55443375 HSD17B6 C
55674497 ADMR C
55690053 TAC3 C
55708569 MYO1A G
55769157 NAB2 G
55775462 STAT6 C
55808543 LRP1 C
55923509 STAC3 C
56114810 INHBC G
56135363 INHBE G
56140201 GLI1 C
56152314 ARHGAP9 C
56196640 DDIT3 C
56210202 DCTN2 G
56230114 KIF5A G
56271253 PIP5K2C C
56305945 GALGT C
56374171 OS9 G
56425051 SAS C
56428272 CDK4 C
56477704 AVIL C
56503617 CTDSP2 C
56621627 NP_150592.1 C
57008431 ENK1 C
NOTE.—The candidate genes in the interval were ar-
ranged in the table by their location on the chromosome,
according to Map Viewer, build 36, and UCSC Genome
Browser.
a G indicates that genomic DNA was sequenced. C in-
dicates that cDNA was sequenced.
and an essential regulator of many cellular processes.9
PIP2 in turn is phosphorylated by phosphatidylinositol-3-
kinase (PI3K) to produce a lipid second messenger, phos-
phatidylinositol-3,4,5-triphosphate (PIP3).
10,11 Two genes
within the LCCS2 locus were chosen on the basis of
their association with the phosphatidylinositol path-
way: PIP5K2C and ERBB3 (GenBank accession number
NM_001982). PIP5K2C catalyzes the phosphorylation
of phosphatidylinositol-5-phosphate (PI5P) to generate
PIP2,
7,8 and ERBB3 binds p85, a regulatory unit of PI3K.12
Whereas no mutation was found in PIP5K2C or in the
coding sequence of ERBB3, an ArG substitution 8 bp 5′
of exon 11 (IVS10-8ArG) of ERBB3 was identiﬁed in all
LCCS2-affected patients of family A (ﬁg. 3A and 3C). An
identical homozygous substitution was found in the af-
fected individual of family B. Primers used to amplify the
exons and ﬂanking intron sequences of ERBB3 from ge-
nomic DNA in LCCS2-affected patients are listed in table
2.
The ArG mutation in ERBB3 abolishes an MmeI restric-
tion site. Restriction-analysis screening for the mutation
in all available family members (of families A and B) and
in 170 additional unrelated Bedouin individuals was per-
formed (ERBB3 exon 11 was ampliﬁed using PCR primers
ex11F [5′-CAC TGG CAT AAA TTG CGG TA-3′] and ex11R
[5′-CAT TGC CTG AAG ATG CCA TT-3′]). All obligate car-
riers in families A and B were shown to be heterozygous
for the mutation. The mutation segregated with the dis-
ease in 67 affected and unaffected individuals in extended
families A and B, whereas none of 170 unrelated Bedouins
carried the mutation (data not shown). To evaluate the
effects of the mutation on the splice site, in silico analysis
was done using the Neural Networks Splice Site Prediction
software (Berkeley Drosophila Genome Project). Although
the mutation did not alter the original acceptor site, an
alternative acceptor splice site was predicted (ﬁg. 4). The
alternative splice site was conﬁrmed in vitro through se-
quence analysis of cDNA from LCCS2-affected patients,
which showed that the IVS10-8ArG mutation resulted in
aberrant alternative splicing, causing an insertion of 8 ba-
ses between exons 10 and 11 (ﬁg. 3B and 3D). In all four
affected individuals fromwhom ﬁbroblasts were available,
the sole transcript found was the one with the aberrant
splicing. The primers used for PCR ampliﬁcation and for
sequencing were CDS_ex11F (5′-GTG GAC TCG AGC AAC
ATT GA-3′) and CSD_ex11R (5′-TAC GCC CAG CAC TAA
TTT CC-3′). The insertion in position 1183 of the ERBB3
mRNA resulted in a frameshift leading to missense coding
beginning at amino acid 395 and an early stop codon
generating a 399-aa protein in place of the native 1,341-
aa protein (ﬁg. 3E).
ERBB3 encodes an epidermal growth factor (EGF) re-
ceptor, one of four transmembrane glycoprotein EGF re-
ceptor tyrosine kinases: ErbB1 (also called “EGFR” or
“HER1”), ErbB2 (HER2 or Neu), ErbB3 (HER3), and ErbB4
(HER4). Members of this family play a key role in regu-
lation ofmammalian cell survival, proliferation, adhesion,
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Table 2. Primers Used for Sequencing the Genomic DNA of
ERBB3
Primer
Primer Sequence
(5′r3′)
Forward Reverse
ERBB3_ex1 TCTTGCCTCGATGTCCTAGC TGAGACCGTGCCCATACC
ERBB3_ex2 AATTTGTGTCCAGCCCTCAG AGCCCTGAAGAAGGAAGGAG
ERBB3_ex3 AATGCCTGAAGGAGGAGAGG TGGGTCATCATCAAGGAGGT
ERBB3_ex4 TGGATGGGTGGAGAGGTAAG ACTCTGGTTTGGTGGGACTG
ERBB3_ex5–7 CAAGCCTTTCTTAGCCCTGA GATTGATTGCACCATTGCAC
ERBB3_ex6 ATGAGCAGTGGCCTCAGAAT CCCCTACCTCCTCCTCAAAG
ERBB3_ex8–9 AGGGATCTAGGGTGGCAGAT CTGGGGTCTAAGGAGGGAAG
ERBB3_ex10–12 ATCCCAGCCATTTCTCCAAG GTCCTTTCAGCCCTCTCCTC
ERBB3_ex11 CACTGGCATAAATTGCGGTA CATTGCCTGAAGATGCCATT
ERBB3_ex12 GGGATTCCCTCTCAGTGGAT GTCCTTTCAGCCCTCTCCTC
ERBB3_ex13–15 AGGCTGGAAGCAGTAACGAG CCAGCTGGGAGTGATTCTTG
ERBB3_ex16–7 CCTCTGCTGTCCAAGCTCTC GGAAAGAGGAGGGGAGTGAC
ERBB3_ex18–20 TCCAGGACTAACGGTGCTTC CCCCCAGACAAGCAGTTCT
ERBB3_ex20 CAGGGTCCTGTGCTTCTCAG CCCCCAGACAAGCAGTTCT
ERBB3_ex21 GATTTGGGGGAATTCCAGAT ATCTGCTTGCCTCTGGAAGA
ERBB3_ex22 CGGCATGCATCTGTACTCC GAAGTGAAGGGAAGGCAGAA
ERBB3_ex23 ACCTTTTGAGACCCCCTCTT AGAGGCGGAGGTTGTAGTGA
ERBB3_ex24–26 GTCTCAAAGTCCCGACCTCA TCCTAAAACCCAGCCTCTCA
ERBB3_ex27 GGCGACAAGAACAAGACTCC GGGGAAAGAATTCGAGGAAA
ERBB3_ex28 CCCCTACCCTCATGAAGTTCT GCCATTAAATGCTCCCTGAG
Figure 3. Sequence analysis of the ERBB3 gene in an LCCS2-affected individual. A, Homozygosity for the GrA substitution in intron
10 (affected individual 61). B, Insertion (8 bp) in the cDNA sequence at position 1183 of the ERBB3 gene. chr p Chromosome; exp
exon. C, Schematic representation of the chromosomal locus, the genomic DNA of ERBB3, and the IVS10-8ArG mutation. D, The splice
variation occurring in affected individuals. E, Schematic illustration of the protein structure of ErbB3 (according to InterPro) and the
predicted mutant truncated protein (395FS399Stop). RLD p Recep_L_domain; FU p Furin-like domain.
and differentiation. Overexpression of ErbB receptors has
been reported in various human cancers. To date, no hu-
man phenotype has been associated with loss of function
of any of these receptors. ErbB receptors contain an ex-
tracellular region, a transmembrane domain, and a cyto-
plasmic tyrosine kinase domain. The putative protein
structure of ErbB3, according to InterPro (EMBL-EBI), is
illustrated in ﬁgure 3E. The truncated ERBB3 protein lacks
part of the extracellular region, the transmembrane do-
main, the entire tyrosine kinase domain, and the proline-
rich carboxy-terminal tail. An alternative transcriptional
splice variant encodes a short isoform of the ErbB3 pro-
tein, isoform s, which lacks the transmembrane regionand
is secreted outside the cell. This isoform acts to regulate
the long isoform 1.13 The mutation demonstrated in the
LCCS2-affected patients affects only isoform 1, leaving the
secreted isoform (isoform s) unaffected. Activation of the
ErbB kinases requires binding of a ligand of the EGF or
heregulin (also called “Neuregulin” [NRG]) family. NRGs
are predominantly expressed in the embryonic CNS and
peripheral nervous systems.14 In response to ligand-spe-
ciﬁc binding, the ErbB receptors form homo- or hetero-
dimers, which in turn initiate tyrosine kinase activity in
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Figure 4. Splice-site prediction with use of the Neural Networks Splice Site Prediction software (Berkeley Drosophila Genome Project).
An alternative additional acceptor splice site was predicted for the ERBB3-mutated sequence.
the intracellular domain by recruiting a different set of
Src homology 2 (SH2) domain–containing proteins,which
lead to a signaling pathway. ErbB3 is known to hetero-
dimerize with ErbB2 (Her2), causing NRG-dependent ac-
tivation of the PI3K pathway. The ErbB2/ErbB3 dimer is
unique in that ErbB2 has the tyrosine kinase activity,
whereas ErbB3 (whose tyrosine kinase domain is inactive)
does the ligand binding through its extracellular domain.
The mutation found in patients with LCCS2 abrogates the
ERBB3 domains known to bind both ERBB2 and the p85
regulatory unit of PI3K. Thus, the LCCS2 mutation is ex-
pected to abolish the PI3K-activating function of the
ErbB2/ErbB3 dimer.
In mice, ErbB receptors mediate cellular growth and dif-
ferentiation in multiple tissues, both in the developing
embryo and in the adult. Null mutations of any of the
ErbB family members result in embryonic lethality in
mice, with defects observed in organs, including the brain,
heart, skin, lung, and gastrointestinal tract, depending on
the receptor affected.15 The human disease caused by a
homozygous defect in ERBB3 is reminiscent of the phe-
notype of the null mutant of its mouse orthologue. Most
ErbB3-knockout embryos die before birth. The few that
develop to term are slightly reduced in size, do not move
or react to tactile stimulation, fail to breathe, and die
shortly after birth. Homozygous ErbB3-mutant embryos
lack Schwann-cell precursors and Schwann cells that nor-
mally accompany peripheral axons of sensory and motor
neurons. It should be noted that NRG is highly expressed
in Schwann cells. Thus, the speciﬁc effect on Schwann
cells seen in ErbB3-null mutant mice is in agreement with
the known NRG-mediated action of ERBB2-ERBB3 dimers
in activating the PI3K pathway.
Neuronal apoptosis has been clearly demonstrated in
the LCCS2 phenotype,2 as well as in the homologous
Erbb3/ mouse model16; in Erbb3/ mice, the initial de-
velopment of motor neurons and sensory neurons of dor-
sal root ganglia occurs as it should, but, at later stages,
most motor neurons and sensory neurons in dorsal root
ganglia undergo cell death. By embryonic day 18.5, the
number of motor neurons in the ventral horn of the spinal
cord is markedly reduced,16 in line with the anterior-horn
atrophy in the human LCCS2 phenotype.2 PI3K phos-
phorylates PIP2 to produce PIP3, a second messenger that
is essential for the translocation of Akt to the plasma
membrane. The PI3K/Akt pathway, a critical survival path-
way in neurons and in most cell types, is regulated by
ErbB2/ErbB3 heterodimers through heregulin.17 Thus, the
neuronal apoptosis seen in the human and mouse ErbB3
defects is likely mediated through downregulation of the
Akt pathway. In yeast, in vivo conversion of the essential
PIP2 pool into PIP3 by PI3K impairs yeast growth by al-
tering morphogenesis and vesicular trafﬁcking.18 We have
shown6 that LCCS3, with a phenotype similar to that of
LCCS2, is caused by amutation in PIP5K1C that is essential
for the synthesis of PIP2—the substrate of PI3K. Thus, de-
fects in the phosphatidylinositol pathway, altering neu-
ronal concentrations of PIP3 or its precursor PIP2, can lead
to defective synaptic vesicular trafﬁcking and enhanced
neuronal apoptosis, culminating in a human phenotype
of congenital arthrogryposis.
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